AGP Picks
View all

Africa Daily Journal: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Africa Daily Journal.

Press releases published on November 4, 2026

Processa Pharmaceuticals Announces Key Leadership Appointments
Septerna Announces Selection of SEP-204 as Development Candidate for Graves' Disease and TED and Reports Preclinical Data at the 2026 American Thyroid Association Annual Meeting
UroGen Reports $68.0 Million of ZUSDURI Revenue and Provides Third Quarter 2026 Financial Results and Highlights
Greenland Mines Welcomes Greenland Parliament’s Approval of Landmark U.S.-Denmark-Greenland Security Agreement
Actuate Therapeutics to Present Promising Preclinical Data Demonstrating Antitumor and Immune Activation Activity of Elraglusib Oral Tablet in Advanced Melanoma Models at ENA 2026
Neuronetics Reports Third Quarter 2026 Financial and Operating Results
Structure Therapeutics to Participate in the Jefferies Global Healthcare Conference
Strifor Expands Its Range of Free Trading Tools for MetaTrader 5
Lifecore Biomedical Reports Financial Results for the Third Quarter Ended September 30, 2026, and Provides Corporate Update
BioCryst Reports Third Quarter 2026 Financial Results
Odyssey Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update 
Verano Expands Florida Retail Footprint to 87 Locations with Grand Opening of MÜV Fernandina Beach, the Company’s 164th Dispensary Nationwide
Brunswick Exploration Reports 1.73% Li2O Over 302 Meters Including 142 Meters at 1.97% Li2O at the Anatacau Main Project
Aya Gold & Silver Drill Results Confirm High-Grade Continuity at Boumadine; New Permits Secured
Rapport Therapeutics Reports Third Quarter 2026 Financials and Provides Business Update
Medicenna Completes Phase 1/2 ABILITY-1 Enrollment and Announces Webinar to Discuss Updated MDNA11 Results with Key Opinion Leaders
PrimeXBT Launches AI-Assisted Trading with MCP Integration, Connecting ChatGPT and Claude to Trading Accounts
Nxera Pharma Revises Consolidated Financial Forecast   for the Year Ending 31 December 2026
Nxera Pharma Enters into Global License Agreement with AbbVie for NXE0033744, a Novel EP4 Receptor Agonist for Inflammatory Bowel Disease
Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Africa Daily Journal

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.